Omega Therapeutics, Inc. (NASDAQ: OMGA) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its price target lowered by analysts at Piper Sandler from $9.00 to $4.00. They now have an "overweight" rating on the stock.
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications